The Lead Episode 150: Heart Rhythm 2026 Late-Breaker Coverage: A Discussion of Total Fatal Adverse Events Following Atrial Fibrillation Ablation Reported in an FDA Mandatory Reporting System: A Matter of Concern? The TiFFANY Study-The Lead Episode 150 Speaker Information

The Lead Episode 150 Speaker Information

Pdf Summary

The document is a brief event slide for <strong>Heart Rhythm 2026 Late-Breaker coverage</strong>. It introduces a discussion titled <strong>“Total Fatal Adverse Events Following Atrial Fibrillation Ablation Reported in an FDA Mandatory Reporting System: A Matter of Concern? The TiFFANY Study.”</strong>

The session is hosted by <strong>Melissa E. Middeldorp, MPH, PhD</strong> from the <strong>University of Adelaide</strong>. Two contributors are listed:
- <strong>James Freeman, MD, MPH, Msci</strong> — Yale University School of Medicine
- <strong>Christopher F. Liu, MD, FHRS</strong> — Weill Cornell Medicine / NewYork-Presbyterian Hospital

The slide also includes <strong>disclosure statements</strong>. Melissa E. Middeldorp reports nothing to disclose. James Freeman reports research support from the <strong>American College of Cardiology</strong> and the <strong>National Institutes of Health</strong>, advisory roles with <strong>Medtronic</strong> and <strong>Pacemate</strong>, and honoraria/speaking/teaching/consulting relationships with <strong>Boston Scientific</strong> and <strong>Biosense Webster, Inc.</strong>

Overall, this document is a title-and-presenter slide for a cardiology conference session focused on safety concerns related to atrial fibrillation ablation and fatal adverse events reported through an FDA mandatory reporting system.

Keywords

Heart Rhythm 2026

Late-Breaker

atrial fibrillation ablation

fatal adverse events

FDA mandatory reporting system

TiFFANY Study

cardiology conference

Melissa E. Middeldorp

James Freeman

Christopher F. Liu